Septerna, Inc.
HealthcareNASDAQ:SEPN · NASDAQ Global Select
+$1.92 today
Vol 0.48M · Avg 0.31M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-12.8%
avg -10.2%
ROIC
-15.8%
avg -8.1%
ROA
-8.2%
avg -5.2%
Analysis
ROA is currently the strongest return metric at -8.2% versus its period average of -5.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jeffrey T. Finer | Co-Founder, Chief Executive Officer & Director | $1.04M | — | 59 | $400,000.00 | 0.89% |
Elizabeth Bhatt | President & Chief Operating Officer | $735,000.00 | — | 58 | $178,209.00 | 0.40% |
Gilbert Labrucherie | Chief Financial Officer | $711,727.00 | — | 54 | $125,000.00 | 0.28% |
Samira Shaikhly | Chief People Officer | $536,487.00 | — | 56 | $6,728.00 | 0.01% |
Jae Kim FACC | Chief Medical Officer | $486,288.00 | — | 56 | $125,000.00 | 0.28% |
George Xu | Senior Director of Corporate Development & Portfolio Strategy | — | — | — | — | — |
Mark A. Wilson | Chief Legal Officer | — | — | 54 | $165,000.00 | 0.37% |
Arthur Christopoulos BPHARM | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board | — | — | — | — | — |
Robert J. Lefkowitz | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board | — | — | 82 | — | — |
Richard Hansen | Vice President of Technology | — | — | — | — | — |
Patrick Sexton | Co-Founder and Member of Cross-Functional Scientific & Drug Discovery Advisory Board | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
12
$2.78M
Net Sentiment
$2.78M
Net selling
Most Active
Shaikhly Samira
6 transactions
1–10 of 12
Analysis
Insiders reported 0 buys worth $0.00 and 12 sells worth $2.78M over the last 12 months. That adds up to net selling of $2.78M. Shaikhly Samira was the most active insider with 6 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | +14.3% (5yr)3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Forward estimates point to Revenue at +14.3% (5yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.59B
Fortrea Holdings Inc.
NASDAQ:FTRE
$1.56B
Nurix Therapeutics, Inc.
NASDAQ:NRIX
$1.47B
Bicara Therapeutics Inc. Common Stock
NASDAQ:BCAX
$1.19B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.09B
Arbutus Biopharma Corporation
NASDAQ:ABUS
$841.51M
Kura Oncology, Inc.
NASDAQ:KURA
$803.41M
Maravai LifeSciences Holdings, Inc.
NASDAQ:MRVI
$722.58M
Prime Medicine, Inc.
NASDAQ:PRME
$501.21M
ProKidney Corp.
NASDAQ:PROK
$242.99M
Who manages SEPN?
Septerna, Inc. (SEPN) lists 11 active executives. The top listed executive is George Xu, Senior Director of Corporate Development & Portfolio Strategy.
Are SEPN insiders buying or selling?
Recent insider activity shows net buying of $35.42M.
Explore More
Continue the stock analysis
Jump to another research area for this company.